Giant Cell Arteritis: Overcoming the Limitations of Conventional Agents with Biologic Therapy

1.50 CME
0 MINS
$0 FEE
SAVE

Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from Genentech, Inc.

Target Audience: The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with giant cell arteritis (GCA).

Learning Objectives: Upon successful completion of this activity, participants should be better able to:

  • Review the pathophysiology and clinical symptomology of GCA. 
  • Examine the short- and long-term complications associated with GCA as well as the importance of early diagnosis and treatment. 
  • Identify patients with GCA in a timely and accurate manner based on appropriate clinical work-up and diagnostic modalities 
  • Examine the advantages and disadvantages of conventional treatments for the management of GCA and related vasculitides.
  • Apply knowledge of the latest clinical evidence to the optimal treatment of patients with GCA.

Activity Chair:
Leonard H. Calabrese, DO 
Professor of Medicine 
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University 
R.J. Fasenmyer Chair of Clinical Immunology 
Vice Chairman, Department of Rheumatic and Immunologic Diseases Orthopaedic and Rheumatologic
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH 

Faculty:
Eamonn Molloy, MD, MS, FRCPI

Clinical Professor
University College of Dublin School of Medicine 
Consultant Rheumatologist 
St. Vincent’s University Hospital 
Elm Park, Dublin 

John H. Stone, MD, MPH
Professor of Medicine
Harvard Medical School
The Edward Fox Chair in Medicine
Director, Clinical Rheumatology
Massachusetts General Hospital
Boston, MA

Reviewer:
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 31, 2018 to January 30, 2019.

How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationships:
Leonard H. Calabrese, DO 
Institute Consulting Fee: Amgen, GlaxoSmithKline, Horizon, Janssen, Pfizer, Regeneron, Sanofi, UCB
Speakers Bureau:
AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Janssen, UCB

Eamonn Molloy, MD, MS, FRCPI
Fees for Non-CME Services: Roche 
Contracted Institute Research: Bristol-Myers Squibb 

John H. Stone, MD, MPH
Consulting Fee: Genentech/Roche

Reviewer reports the following relationship(s):
Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at cme@vindicoCME.com